| Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus DZI Cherney, BA Perkins, N Soleymanlou, M Maione, V Lai, A Lee, ... Circulation 129 (5), 587-597, 2014 | 1400 | 2014 |
| Cardiovascular outcomes with ertugliflozin in type 2 diabetes CP Cannon, R Pratley, S Dagogo-Jack, J Mancuso, S Huyck, ... New England Journal of Medicine 383 (15), 1425-1435, 2020 | 1371 | 2020 |
| Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications HJL Heerspink, BA Perkins, DH Fitchett, M Husain, DZI Cherney Circulation 134 (10), 752-772, 2016 | 1290 | 2016 |
| Empagliflozin in patients with chronic kidney disease EMPA-Kidney Collaborative Group New England Journal of Medicine 388 (2), 117-127, 2023 | 1160 | 2023 |
| Sotagliflozin in patients with diabetes and chronic kidney disease DL Bhatt, M Szarek, B Pitt, CP Cannon, LA Leiter, DK McGuire, JB Lewis, ... New England Journal of Medicine 384 (2), 129-139, 2021 | 971 | 2021 |
| Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis DK McGuire, WJ Shih, F Cosentino, B Charbonnel, DZI Cherney, ... JAMA cardiology 6 (2), 148-158, 2021 | 889 | 2021 |
| The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus DZI Cherney, BA Perkins, N Soleymanlou, R Har, N Fagan, OE Johansen, ... Cardiovascular diabetology 13, 1-8, 2014 | 540 | 2014 |
| Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials Y Lytvyn, P Bjornstad, JA Udell, JA Lovshin, DZI Cherney Circulation 136 (17), 1643-1658, 2017 | 523 | 2017 |
| American heart association council on E, prevention statistics c, stroke statistics s. heart disease and stroke statistics-2019 update: a report from the American heart association EJ Benjamin, P Muntner, A Alonso, MS Bittencourt, CW Callaway, ... Circulation 139 (10), e56-e528, 2019 | 512 | 2019 |
| Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the … DZI Cherney, B Zinman, SE Inzucchi, A Koitka-Weber, M Mattheus, ... The lancet Diabetes & endocrinology 5 (8), 610-621, 2017 | 410 | 2017 |
| Renoprotective effects of sodium-glucose cotransporter-2 inhibitors HJL Heerspink, M Kosiborod, SE Inzucchi, DZI Cherney Kidney international 94 (1), 26-39, 2018 | 374 | 2018 |
| The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure MC Thomas, DZI Cherney Diabetologia 61, 2098-2107, 2018 | 349 | 2018 |
| Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials J Rosenstock, J Marquard, LM Laffel, D Neubacher, S Kaspers, ... Diabetes care 41 (12), 2560-2569, 2018 | 326 | 2018 |
| Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials C Baigent, JR Emberson, R Haynes, WG Herrington, P Judge, ... The Lancet 400 (10365), 1788-1801, 2022 | 294 | 2022 |
| Serum urate lowering with allopurinol and kidney function in type 1 diabetes A Doria, AT Galecki, C Spino, R Pop-Busui, DZ Cherney, I Lingvay, ... New England Journal of Medicine 382 (26), 2493-2503, 2020 | 293 | 2020 |
| Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial BA Perkins, DZI Cherney, H Partridge, N Soleymanlou, H Tschirhart, ... Diabetes care 37 (5), 1480-1483, 2014 | 284 | 2014 |
| Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers CCJ Dekkers, S Petrykiv, GD Laverman, DZ Cherney, RT Gansevoort, ... Diabetes, Obesity and Metabolism 20 (8), 1988-1993, 2018 | 255 | 2018 |
| Vascular dysfunction in women with a history of preeclampsia and intrauterine growth restriction: insights into future vascular risk Y Yinon, JCP Kingdom, A Odutayo, R Moineddin, S Drewlo, V Lai, ... Circulation 122 (18), 1846-1853, 2010 | 255 | 2010 |
| Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging K Kidokoro, DZI Cherney, A Bozovic, H Nagasu, M Satoh, E Kanda, ... Circulation 140 (4), 303-315, 2019 | 243 | 2019 |
| Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin DZI Cherney, ME Cooper, I Tikkanen, E Pfarr, OE Johansen, HJ Woerle, ... Kidney international 93 (1), 231-244, 2018 | 242 | 2018 |
Bruce A. PerkinsProfessor of Medicine, Endocrinology and Metabolism, University of Toronto在 sinaihealthsystem.ca 的电子邮件经过验证
